...
Dryness & GSM faq

Is discomfort with sex always due to dryness?

Not always. Vaginal dryness from genitourinary syndrome of menopause (GSM) is a common cause of dyspareunia, but discomfort can also come from arousal issues, pelvic floor muscle tightness, contact dermatitis, vulvodynia/vestibulodynia, infections, skin conditions like lichen sclerosus, or medication effects. A step-wise plan—gentle vulval care, regular moisturisers, the right lubricant, and, if needed, local oestrogen or DHEA—often helps. Seek review for red flags or persistent pain. Educational only. Results vary. Not a cure.

Clinical Context

Who might suit which options? If dryness is dominant with stinging or micro-tears, schedule moisturisers and add a silicone-based lubricant for intimacy; consider local oestrogen or vaginal DHEA if symptoms persist. If penetration feels sharp or burning at the entrance with normal lubrication, pelvic floor overactivity or vestibulodynia may be the primary driver—prioritise pelvic health physiotherapy, dilator work, and psychosexual therapy alongside gentle skin care. If itching, odour, or clumpy/thin grey discharge is present, test for thrush or BV rather than assuming GSM.

Who should avoid or delay some options? Postpartum or post-surgery healing, active genital infections, unhealed tears, or unexplained bleeding warrant assessment before new products or procedures. People with a history of hormone-sensitive cancers should discuss local oestrogen or DHEA with oncology and menopause teams; some still choose local therapy after shared decision-making. Alternatives for those avoiding hormones include long-term moisturiser routines (often with hyaluronic acid), pelvic floor physiotherapy, and psychosexual strategies. Plan a follow-up in 6–12 weeks to review comfort and adjust to the lowest effective maintenance.

Evidence-Based Approaches

Guidelines recommend a step-wise pathway. The NICE Menopause Guideline (NG23) advises offering information on vaginal moisturisers and lubricants and considering low-dose local vaginal oestrogen for GSM when symptoms affect quality of life. Systemic HRT may help vasomotor symptoms but often needs to be paired with local therapy for dyspareunia linked to GSM. Choice of local product (estradiol/estriol cream, pessary/tablet, or estradiol ring) reflects preference, dexterity, and symptom pattern, with many continuing maintenance after symptom relief.

Cochrane syntheses show that low-dose vaginal oestrogens improve dryness, soreness, dyspareunia and vaginal pH versus placebo, with broadly similar efficacy across formulations and low systemic absorption at licensed doses. See the Cochrane Library for pooled estimates and safety data. NHS information on painful sex and vaginal dryness offers practical self-care and red flags.

Peer-reviewed reviews indexed on PubMed outline GSM mechanisms and management (moisturisers, lubricants, local oestrogen, vaginal DHEA, pelvic floor and psychosexual approaches). Dermatology guidance from the British Association of Dermatologists supports diagnosis of lichen sclerosus, a frequent mimic that needs specific treatment, not just lubrication. Together, these sources support starting with non-hormonal basics, escalating to local hormonal therapy when appropriate, and addressing pelvic floor and psychosexual contributors where relevant.